Larimar Therapeutics Files 8-K Report

Ticker: LRMR · Form: 8-K · Filed: Jun 10, 2024 · CIK: 1374690

Larimar Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyLarimar Therapeutics, Inc. (LRMR)
Form Type8-K
Filed DateJun 10, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: regulatory-filing, 8-K

Related Tickers: LRMR

TL;DR

Larimar Therapeutics filed an 8-K, mostly boilerplate with exhibits.

AI Summary

On June 10, 2024, Larimar Therapeutics, Inc. filed an 8-K report. The filing primarily serves as a notification of other events and includes financial statements and exhibits. No specific material events or transactions were detailed in the provided excerpt.

Why It Matters

This filing indicates Larimar Therapeutics is making a regulatory submission to the SEC, which could contain updates on company operations or financial status.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report and does not disclose any new material risks or adverse events.

Key Players & Entities

  • Larimar Therapeutics, Inc. (company) — Registrant
  • ZAFGEN, INC. (company) — Former Company Name
  • June 10, 2024 (date) — Date of Report

FAQ

What is the primary purpose of this 8-K filing for Larimar Therapeutics, Inc.?

The primary purpose of this 8-K filing is to report 'Other Events' and to include 'Financial Statements and Exhibits'.

What was Larimar Therapeutics, Inc.'s former name?

Larimar Therapeutics, Inc.'s former name was ZAFGEN, INC.

On what date was this 8-K report filed?

This 8-K report was filed on June 10, 2024.

In which state is Larimar Therapeutics, Inc. incorporated?

Larimar Therapeutics, Inc. is incorporated in Delaware.

What is the principal executive office address for Larimar Therapeutics, Inc.?

The principal executive office address is Three Bala Plaza East, Bala Cynwyd, Pennsylvania, 19004.

Filing Stats: 464 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-06-10 06:05:35

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share LRMR Nasdaq Global Market

Filing Documents

01 Other Events

Item 8.01 Other Events. On June 10, 2024, Larimar Therapeutics, Inc. (the " Company ") posted on its website an updated slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the presentation in various meetings with investors, analysts and other parties from time to time.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Below is a list of exhibits included with this Current Report on Form 8-K. Exhibit No. Document 99.1 Larimar Therapeutics, Inc. Corporate Presentation, dated June 10, 2024* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Larimar Therapeutics, Inc. Date: June 10, 2024 By: /s/ Carole S. Ben-Maimon, M.D. Name: Carole S. Ben-Maimon, M.D. Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.